DaVita Q4 2025 results, FY2025 review, and 2026 outlook

If you are looking at DaVita stock, it is easy to focus only on the headline numbers.

Revenue up. Earnings mixed. Guidance looks better.

But with a company like DaVita, the real story sits beneath the surface. You need to look at treatment volumes, reimbursement changes, payer mix, labour costs, drug economics, and debt. That is where the investment case becomes clearer.

In this article, let us break down DaVita’s Q4 2025 results, compare FY2025 vs FY2024, and look at DaVita’s 2026 risks, drivers, and outlook.

Before we go further, a quick disclaimer: I am a shareholder of DaVita, so this is not investment advice. This is how I think through the business as an investor.

DaVita Q4 2025 results

DaVita’s most recent reported quarter was Q4 2025, and overall, the quarter came in solid.

The company reported:

• Revenue: $3.62 billion

• Operating income: $561 million

• Adjusted operating income: $586 million

• Diluted EPS from continuing operations: $2.94

• Adjusted diluted EPS: $3.40

• Operating cash flow: $541 million

• Free cash flow: $309 million

At first glance, these are healthy numbers. DaVita remains a business that generates meaningful cash flow, and that is one reason investors continue to pay attention to it.

Still, the headline numbers do not tell the full story.

The bigger issue is that DaVita remains highly sensitive to treatment volumes. Management said treatment trends in 2025 were affected by higher mortality, a more severe flu season, and fewer treatment days. That matters because dialysis is still a volume-driven business. If patients miss treatments, the impact can show up quickly in financial results.

So while DaVita’s Q4 2025 earnings were respectable, the more important takeaway is this: management is entering 2026 hoping that treatment volumes stabilise while the company benefits from a more supportive reimbursement environment.

That optimism also showed up in guidance. DaVita expects for 2026:

• Adjusted operating income: $2.085 billion to $2.235 billion

• Adjusted diluted EPS: $13.60 to $15.00

• Free cash flow: $1.0 billion to $1.25 billion

That tells us management believes 2026 should be a stronger year than 2025.

Subscribe to our newsletter if you enjoy insights like this.

DaVita FY2025 results vs FY2024

When we zoom out to the full year, DaVita’s FY2025 results were mixed.

For FY2025, the company reported:

• Revenue: $13.643 billion

• Operating income: $2.044 billion

• Adjusted operating income: $2.094 billion

• Diluted EPS from continuing operations: $9.51

• Adjusted diluted EPS: $10.78

• Operating cash flow: $1.887 billion

• Free cash flow: $1.024 billion

Compared with FY2024, revenue increased from $12.816 billion to $13.643 billion. So the top line clearly improved.

But earnings paint a more nuanced picture.

Diluted EPS from continuing operations fell from $10.73 in FY2024 to $9.51 in FY2025. That means reported profitability weakened year over year.

At the same time, adjusted diluted EPS improved from $9.68 to $10.78. So, depending on whether you focus on reported results or adjusted results, the year can look quite different.

To me, the simplest way to read FY2025 is this: DaVita improved revenue per treatment, but treatment volume stayed weak.

That is important.

DaVita’s average patient service revenue per treatment in U.S. dialysis increased from $391.32 in 2024 to $409.56 in 2025. That was helped by reimbursement changes and the inclusion of phosphate binders in the ESRD payment bundle.

So the company earned more per treatment.

But the other side of the story is that normalised non-acquired treatment growth was-0.8% in 2025. In other words, DaVita got more revenue per treatment, but the volume environment remained soft.

That is why FY2025 was not a clean earnings story. It was more of a balancing act. Better pricing and reimbursement helped offset weaker volumes and other cost pressures.

There were also additional headwinds.

DaVita recorded around $25 million of cybersecurity-related charges in 2025. On top of that, interest expense remained meaningful because the company still carries a large debt load. At the end of FY2025, DaVita had more than $10 billion in debt principal outstanding.

That does not mean the company is broken. But it does mean investors should not ignore the balance sheet. A leveraged business simply has less room for error.

One bright spot in 2025 was Integrated Kidney Care, or IKC.

This segment increased revenue from $504 million in FY2024 to $542 million in FY2025. More importantly, operating income improved from an $18 million loss to a $22 million profit.

That may not be the core driver of the DaVita investment case today, but it is still worth watching. If IKC keeps improving, it could become a more meaningful earnings contributor over time.

Subscribe to our newsletter if you enjoy insights like this.

What will drive DaVita in 2026?

As we move into 2026, the story comes down to a few key drivers.

1. Better reimbursement

One of the clearest tailwinds for DaVita in 2026 is reimbursement.

CMS has finalised a payment update that should increase ESRD facility payments by about 2.2% in 2026. For a company like DaVita, even a modest reimbursement increase matters because the business is built on recurring treatments.

A better reimbursement environment can support both revenue and margins.

2. Phosphate binder economics

Another driver is the ongoing impact of phosphate binders.

These are medicines used to help dialysis patients manage phosphorus levels. For DaVita, they now affect both revenue and cost within the payment system.

That means phosphate binders can help earnings, but only if the economics are managed well. This is not a simple one-way tailwind.

3. Integrated Kidney Care improvement

IKC is still much smaller than DaVita’s core dialysis business, but it is improving.

If this segment continues to grow and stay profitable, it could give DaVita a second earnings lever beyond traditional dialysis centre performance. That matters because it adds another path for growth.

Want a concise version of Charlie Munger’s 25 human misjudgements? Download here!

DaVita 2026 risks investors should watch

Of course, the 2026 story is not only about the upside. There are real risks here too.

1. Treatment volume risk

This is still the biggest one.

If mortality remains elevated, flu-related disruption continues, or patients continue missing treatments, then better reimbursement alone may not be enough to drive strong earnings growth.

For me, this is the single most important thing to monitor in DaVita’s 2026 outlook.

2. Payer mix risk

DaVita earns a large part of its profit from higher-paying commercial plans.

If the payer mix shifts more toward lower-paying government plans, or if commercial pricing weakens, margins can come under pressure. This may not always show up clearly in one quarter, but over time it can have a major impact on profitability.

3. Labour and cost pressure

Labour remains a major cost item.

Higher wages, staffing pressures, and rising patient care costs can all eat into the benefit from better reimbursement. Even phosphate binders, while helpful on revenue, can also increase treatment-related costs depending on how the economics play out.

4. Debt and balance sheet risk

DaVita is not a fragile business, but it is a leveraged business.

That means execution matters more. If operations improve, the balance sheet is manageable. But if volumes stay weak or costs rise unexpectedly, leverage becomes more of a concern.

DaVita 2026 outlook

So what is the overall outlook for DaVita in 2026?

I would describe it as constructive, but volume-sensitive.

There are good reasons to believe 2026 could be better than 2025. Reimbursement is supportive. Management’s guidance is stronger. IKC is improving. And the business remains highly cash generative.

But this is not a company where you can assume the tailwinds will do all the work.

For DaVita to deliver a strong 2026, management likely needs to get three things right:

• stabilise treatment volumes

• protect commercial payer economics

• control labour and operating costs

If these line up, 2026 could be a meaningful step forward.

If they do not, then the year may end up looking much less attractive than the current guidance suggests.

DaVita’s valuation

Let us talk about valuation.

I have revised my valuation for DaVita using the discounted cash flow method, and based on my latest assumptions, I arrive at an intrinsic value of $395.14.

In DaVita’s case, I see this as a narrow-moat business. It has a strong position in dialysis, but it is not the kind of company where I would get too comfortable paying close to fair value. On top of that, I do not particularly like its current debt level. The business is cash generative, yes, but leverage still reduces the margin for error.

Because of that, I would want a much wider buffer before committing fresh capital.

So instead of buying anywhere near my estimated intrinsic value, I would apply a 50% margin of safety. That brings my preferred buy level to around $198.00.

In other words, I would invest only the next tranche if DaVita’s stock price falls below $198.00.

That may sound conservative, but for a business with a narrow moat and a leveraged balance sheet, I think it is the right approach. Sometimes the goal is not just to find a good company. It is to make sure you are entering at a price that gives you enough room if things do not go exactly as planned.

Let me know in the comments what you think of DaVita’s intrinsic value.